Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Artiva Biotherapeutics Readies for the Next Phase of Growth with the Appointment of Neha Krishnamohan as CFO and EVP, Corporate Development and Promotion of Jennifer Bush to Chief Operating Officer
Read Article
News
2024
2023
Archive
Search news articles
October 17, 2023
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Spontaneous Urticaria
October 16, 2023
NodThera Announces First Patients Dosed in a Phase Ib/IIa Cardiovascular Risk Trial of NLRP3 Inflammasome Inhibitor NT-0796
October 10, 2023
Precede Biosciences Emerges From Stealth to Dramatically Impact Precision Medicine with a First-In-Class Liquid Biopsy Platform
September 27, 2023
Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial
September 26, 2023
IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations
September 25, 2023
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
September 21, 2023
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 20, 2023
scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives
September 13, 2023
TMRW Life Sciences Receives CE Mark for the CryoRobot Select, its Next-Generation Automated Platform to Safely Manage and Store Frozen Eggs and Embryos
September 12, 2023
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors
« Previous Page
1
…
5
6
7
8
9
…
119
Next Page »